Literature DB >> 27259012

Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers.

Anne M Mills1, Chelsea E Gottlieb, Scott M Wendroth, Christiana M Brenin, Kristen A Atkins.   

Abstract

Apocrine carcinomas comprise ∼1% of all breast cancers and are characterized by large cells bearing abundant eosinophilic granular cytoplasm, round nuclei, and prominent nucleoli. They are typically estrogen receptor/progesterone receptor/HER2 negative, making them unresponsive to typical hormonal or HER2-based chemotherapy. However, this subtype of triple-negative breast cancers expresses androgen receptor (AR), a feature not shared by most nonapocrine triple-negative cancers (NA-TNCs). AR therefore represents a potential diagnostic tool and therapeutic target for apocrine breast carcinoma. All pure apocrine carcinomas diagnosed during a 10-year period were reviewed, and clinicopathologic characteristics were compared with a control group of 26 NA-TNC cases. Twenty apocrine carcinomas were identified (∼0.8% of all breast cancers). The mean age at diagnosis was 69.3 years for apocrine carcinomas and 56.7 years for NA-TNC. All apocrine carcinomas and no NA-TNC were AR positive. The proportions of apocrine carcinoma grades varied, with G1 being seen in 15% of patients, G2 in 55%, and G3 in 30%. In contrast, 100% of NA-TNC cases were G3. The majority of apocrine carcinomas presented at low T stage (T1: 70%; T2: 20%; T3: 10%; T4: 0%), whereas NA-TNC cases more often presented at T2 or higher (T1: 46.2%; T2: 30.8%; T3: 11.5%; T4: 11.5%). Thirty percent of apocrine carcinomas and 30.8% of NA-TNCs had nodal metastases at presentation. Apocrine carcinomas had a favorable clinical prognosis, with 80% of patients showing no evidence of disease-related morbidity or mortality (mean follow-up: 45.2 mo). Pure apocrine carcinomas represent a clinicopathologically distinct subgroup of triple-negative breast cancer characterized by AR positivity. When compared with NA-TNC, apocrine carcinomas more often present in older women with lower grade and T stage, a group in which a more conservative treatment regimen is often desired.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27259012     DOI: 10.1097/PAS.0000000000000671

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

Review 1.  The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.

Authors:  Felipe C Geyer; Fresia Pareja; Britta Weigelt; Emad Rakha; Ian O Ellis; Stuart J Schnitt; Jorge S Reis-Filho
Journal:  Am J Pathol       Date:  2017-07-20       Impact factor: 4.307

Review 2.  Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field.

Authors:  Santiago Escrivá-de-Romaní; Miriam Arumí; Esther Zamora; Meritxell Bellet
Journal:  Breast Care (Basel)       Date:  2018-08-14       Impact factor: 2.860

Review 3.  Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers.

Authors:  Semir Vranic; Rebecca Feldman; Zoran Gatalica
Journal:  Bosn J Basic Med Sci       Date:  2017-02-21       Impact factor: 3.363

4.  Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses.

Authors:  Xuexue Xiao; Su Jin; Geling Zhangyang; Shiwei Xiao; Fang Na; Junqiu Yue
Journal:  Gland Surg       Date:  2022-06

Review 5.  AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.

Authors:  Nina Ditsch; Achim Wöcke; Michael Untch; Christian Jackisch; Ute-Susann Albert; Maggie Banys-Paluchowski; Ingo Bauerfeind; Jens-Uwe Blohmer; Wilfried Budach; Peter Dall; Eva Maria Fallenberg; Peter A Fasching; Tanja N Fehm; Michael Friedrich; Bernd Gerber; Oleg Gluz; Nadia Harbeck; Jörg Heil; Jens Huober; Hans H Kreipe; David Krug; Thorsten Kühn; Sherko Kümmel; Cornelia Kolberg-Liedtke; Sibylle Loibl; Diana Lüftner; Michael Patrick Lux; Nicolai Maass; Christoph Mundhenke; Ulrike Nitz; Tjoung-Won Park-Simon; Toralf Reimer; Kerstin Rhiem; Achim Rody; Marcus Schmidt; Andreas Schneeweiss; Florian Schütz; Hans-Peter Sinn; Christine Solbach; Erich-Franz Solomayer; Elmar Stickeler; Christoph Thomssen; Isabell Witzel; Volkmar Müller; Wolfgang Janni; Marc Thill
Journal:  Breast Care (Basel)       Date:  2022-05-05       Impact factor: 2.268

Review 6.  Pathogenesis of Triple-Negative Breast Cancer.

Authors:  Fatemeh Derakhshan; Jorge S Reis-Filho
Journal:  Annu Rev Pathol       Date:  2022-01-24       Impact factor: 32.350

Review 7.  Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review.

Authors:  F Giugliano; J Uliano; V A A Zia; D Trapani; A Marra; G Viale; E Ferraro; A Esposito; C Criscitiello; P D'amico; G Curigliano
Journal:  Breast Cancer Res Treat       Date:  2021-05-27       Impact factor: 4.872

Review 8.  Rare Breast Cancer Subtypes.

Authors:  Sarah Jenkins; Megan E Kachur; Kamil Rechache; Justin M Wells; Stanley Lipkowitz
Journal:  Curr Oncol Rep       Date:  2021-03-23       Impact factor: 5.075

9.  Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas.

Authors:  Xiangjie Sun; Ke Zuo; Qianlan Yao; Shuling Zhou; Ruohong Shui; Xiaoli Xu; Rui Bi; Baohua Yu; Yufan Cheng; Xiaoyu Tu; Hongfen Lu; Wentao Yang
Journal:  Mod Pathol       Date:  2020-06-05       Impact factor: 7.842

Review 10.  Histology of Luminal Breast Cancer.

Authors:  Ramona Erber; Arndt Hartmann
Journal:  Breast Care (Basel)       Date:  2020-07-15       Impact factor: 2.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.